Creating master cell banks for new SARS-CoV-2 vaccines
Official title: Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines
Funded at Idt Biologika Gmbh · NIH-11080845 · Data updated 2026-11-12
This study is working on creating special cell banks to help make better vaccines for COVID-19, so that patients can have more effective protection against the virus and its variants.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Idt Biologika Gmbh NIH-funded |
| Lab location | 1 site (Dessau-Rosslau, Germany) |
| Project start | May 15, 2018 |
| Project end | May 14, 2028 |
| Funding year | 2024 |
| Award (this year) | $944,900 |
| NIH project number | 272201800011I-0-759302400001-1 |
| Project ID | NIH-11080845 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at risk for COVID-19, particularly those in vulnerable populations or with underlying health conditions.
✕Less likely to help
Patients who are not at risk for COVID-19 or those who have already received effective vaccinations may not receive direct benefits from this research.
What this research studies
This research focuses on developing master cell banks that are essential for manufacturing next-generation vaccines against SARS-CoV-2. It involves a comprehensive approach that includes product development planning, optimization, and compliant manufacturing processes for clinical studies. Patients may benefit from the development of more effective vaccines that can better protect against COVID-19 and its variants. The research also includes regulatory support to ensure that these vaccines meet safety and efficacy standards.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines against SARS-CoV-2, enhancing public health and safety.
How similar studies have gone: Other research has shown success in developing vaccines using similar methodologies, particularly in response to infectious diseases.
Where this research is happening
-
Idt Biologika Gmbh
Dessau-Rosslau, Germany Active
Researchers
- Principal investigator: Trusheim, Heidi — Idt Biologika Gmbh
- Study coordinator: Trusheim, Heidi
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.